In April 2025, Daniel A. Heller, PhD, and Mijin Kim, PhD, co-edited a two-volume reference work on carbon nanomaterials in biomedicine, representing a comprehensive synthesis of the foundational science underlying the nanosensor platform that Nine Diagnostics was built to advance.
Published by World Scientific as part of the World Scientific Series on Carbon Nanoscience, the work spans Volume 11, Carbon Nanotubes in Biomedicine: From Fundamentals to Therapeutic Applications, and Volume 12, Advances in Carbon Nanotube Chemistry, Safety, and Applications in Biomedical Research. Together, the volumes cover the photophysics, surface chemistry, functionalization strategies, safety profiles, and biomedical applications of carbon nanotube-based materials, providing a consolidated resource for researchers working at the intersection of nanotechnology, optical sensing, and disease biology.
Heller, Head of the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center and co-founder and CSO of Nine Diagnostics, has led two decades of research into nanosensor design, near-infrared fluorescence, and liquid biopsy development for cancer. Kim, Assistant Professor of Chemistry and Biochemistry at the Georgia Institute of Technology and co-founder and Scientific Advisor of Nine Diagnostics, has advanced quantum defect engineering of single-walled carbon nanotubes and machine learning approaches to multi-disease fingerprinting. Their co-editorship reflects a sustained collaboration that spans the foundational science of Nine Diagnostics’ multi-omic nanosensor platform.
The handbook is available through World Scientific. The full publication record of the Cancer Nanomedicine Lab at MSKCC documents the broader body of work from which this handbook draws.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.